Conference Coverage

MicroRNAs flag liver damage in HIV-, HCV-infected persons


 

REPORTING FROM CROI


Of the 13 miRNAs, two, labeled miR-99a-5p and miR-100-5p, which belong to the same family of miRNAs, were found to be significantly upregulated in patients with HIV and HCV coinfections that later progressed to liver cirrhosis “even those these patients exhibited no liver fibrosis at the time of sampling,” he said

The two culprit miRNAs were significantly correlated with ALT and AST levels, as well as the degree of liver fibrosis.

A comparison of samples from patients with HIV monoinfection who had elevated ALT or focal nodular hyperplasia with those of patients with HIV infection but normal ALT levels showed that two other miRNAs, miR-122-3p and miR-193b-5p, were highly and significantly upregulated, and correlated with both aminotransferase and liver fibrosis levels.

“This study demonstrates the potential of microRNAs as biomarkers of liver injury progression in HIV-1 infected patients,” Dr. Martinez concluded.

The Spanish Instituto de Salud Carlos III and the Spanish AIDS network funded the study. Dr. Martinez reported having no conflicts of interest.

SOURCE: Martinez MA et al. CROI 2018, abstract 639.

Pages

Recommended Reading

Eradicating HCV significantly improved liver stiffness in meta-analysis
MDedge Family Medicine
Baby boomers are the hepatitis C generation
MDedge Family Medicine
Psychiatric issues common among hepatitis C inpatients
MDedge Family Medicine
Inflammatory markers predict vaccine response in HCV, HIV
MDedge Family Medicine
Viremic suppression linked to decreased MACE rate in patients with HCV-cirrhosis
MDedge Family Medicine
ACIP unanimously recommends HEPLISAV-B
MDedge Family Medicine
HCV infection tied to premature ovarian senescence and a high miscarriage rate
MDedge Family Medicine
NASH rapidly overtaking hepatitis C as cause of liver cancer
MDedge Family Medicine
Alcohol dependence may accelerate aging, frontal cortical deficits
MDedge Family Medicine
Switching to tenofovir alafenamide may benefit HBV patients
MDedge Family Medicine